Shares of Beximco Pharmaceuticals (LON: BXP) today surged 48.2% after the company announced an exclusive deal with the Serum Institute of India to be the sole supplier of the COVID-19 vaccine in Bangladesh.
The deal will see Beximco contribute funds to facilitate the vaccine’s development, which will be adjusted according to the vaccine’s final pricing.
The Serum Institute has partnered with AstraZeneca, the Gates Foundation and Gavi to produce over a billion vaccines for global distribution.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Beximco clarified that the vaccines supplied to Bangladesh will be on a priority basis and that its investment will depend on regulatory approvals, SII’s production capacity and its earlier commitments to other countries.
BXP share price
Source: Tradingview
BXP shares today surged 48.2% to trade at 81.5p having ended yesterday’s session trading at 55.0p.
- AstraZeneca shares recently surged higher on Trump order
- Trade stocks with the highly-rated IG UK, an industry leader
- Find alternative brokers to Hargreaves Lansdown